Skip to main content
. 2006 Nov 2;578(Pt 2):471–479. doi: 10.1113/jphysiol.2006.123588

Figure 5. Summary graph of pharmacology of burst-LTD.

Figure 5

A and B, histograms of EPSP amplitudes after burst-conditioning. A, antagonists that successfully prevented burst-LTD. B, inhibitors that did not interfere with burst-LTD. Dotted and dashed line, average control and burst-conditioned EPSP amplitude, respectively. AIDA, 1-aminoindan-1,5-dicarboxylic acid; AM-251, N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide; BAPTA, 1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid; CDC, cinnamyl 3,4,-dihydroxy-α-cyanocinnamate; CN, calcineurin autoinhibitory peptide (ITSFEEAKGLDRINERMPPR); D15, PPPQVPSRPNRAPPG; D609, O-(octahydro-4,7-methano-1H-inden-5-yl) carbonopotassium dithioate; 19-31, RFARKGALRQKNV; Hep, heparin; Nif, nifedipine; L-NNA, NG.-nitro-l-arginine; RR, ruthenium red; ext, extracellularly applied; int, intracellularly applied.